Outlook Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Outlook Therapeutics

14/02/2025 14:32

* Outlook Therapeutics Inc  OTLK.OQ  reported quarterly
adjusted
earnings of 72 cents​​ per share for the quarter ended December
31, higher than the same quarter last year, when the company
reported EPS of -80 cents.  The mean expectation of six analysts
for the quarter was for a loss of 77 cents per share. Wall
Street expected results to range from -99 cents to -52 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Outlook Therapeutics Inc's reported EPS for the quarter
was 72
cents​.
    * The company reported quarterly net income of $17.38
million.
    * Outlook Therapeutics Inc shares had fallen by 2.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 12.5%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Outlook
Therapeutics Inc is $13.00 
This summary was machine generated from LSEG data February 14 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.77          0.72           Beat
 Sep. 30 2024      -0.83          0.76           Beat
 Jun. 30 2024      -1.00          -0.83          Beat
 Mar. 31 2024      -0.85          -1.55          Missed